These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26174150)

  • 1. Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis.
    Li YY; Zhang WC; Zhang JL; Zheng CJ; Zhu H; Yu HM; Fan LM
    Lipids Health Dis; 2015 Jul; 14():72. PubMed ID: 26174150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis.
    Cao L; Zhang Y; Fu Z; Dong L; Yang S; Meng W; Li Y; Zhang W; Zhang J; Zheng C; Zhu H; Fan L
    J Obstet Gynaecol Res; 2015 Dec; 41(12):1951-8. PubMed ID: 26472266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
    Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
    J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
    Xu Y; Shen Z; Wiper DW; Wu M; Morton RE; Elson P; Kennedy AW; Belinson J; Markman M; Casey G
    JAMA; 1998 Aug; 280(8):719-23. PubMed ID: 9728644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
    Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
    Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer.
    Meleh M; Pozlep B; Mlakar A; Meden-Vrtovec H; Zupancic-Kralj L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):287-91. PubMed ID: 17766199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidic acid: an ovarian cancer marker.
    Sedláková I; Vávrová J; Tosner J; Hanousek L
    Eur J Gynaecol Oncol; 2008; 29(5):511-4. PubMed ID: 19051824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.
    Sedláková I; Vávrová J; Tošner J; Hanousek L
    Tumour Biol; 2011 Apr; 32(2):311-6. PubMed ID: 21061112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysophospholipids are potential biomarkers of ovarian cancer.
    Sutphen R; Xu Y; Wilbanks GD; Fiorica J; Grendys EC; LaPolla JP; Arango H; Hoffman MS; Martino M; Wakeley K; Griffin D; Blanco RW; Cantor AB; Xiao YJ; Krischer JP
    Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1185-91. PubMed ID: 15247129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of total plasma lysophosphatidic acid in ovarian cancer: a meta-analysis.
    Lu Z; Chen Y; Hu Z; Hu C
    Int J Gynecol Cancer; 2015 Jan; 25(1):18-23. PubMed ID: 25398018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors.
    Tokumura A; Tominaga K; Yasuda K; Kanzaki H; Kogure K; Fukuzawa K
    Cancer; 2002 Jan; 94(1):141-51. PubMed ID: 11815970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lysophosphatidic acid in ovarian cancer patients].
    Sedlákova I; Vávrová J; Tosner J; Hanousek L
    Ceska Gynekol; 2006 Jul; 71(4):312-7. PubMed ID: 16956044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis.
    Wang YD; Chen H; Liu HQ; Hao M
    Tumour Biol; 2014 Dec; 35(12):11799-808. PubMed ID: 25192720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-17 SNPs and serum levels increase ulcerative colitis risk: a meta-analysis.
    Li J; Tian H; Jiang HJ; Han B
    World J Gastroenterol; 2014 Nov; 20(42):15899-909. PubMed ID: 25400476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated VEGF levels contribute to the pathogenesis of osteoarthritis.
    Yuan Q; Sun L; Li JJ; An CH
    BMC Musculoskelet Disord; 2014 Dec; 15():437. PubMed ID: 25515407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors.
    Pozlep B; Meleh M; Kobal B; Verdenik I; Osredkar J; Kralj LZ; Meden-Vrtovec H
    Eur J Gynaecol Oncol; 2007; 28(5):394-9. PubMed ID: 17966220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with risk factors have higher plasma levels of lysophosphatidic acid: a promising surrogate marker for blood platelet activation.
    Yao CS; Yan SG; Gao LS; Sun ZR; Liu F; Jiang B; Wang HB; Wu QZ
    Blood Coagul Fibrinolysis; 2014 Jun; 25(4):322-5. PubMed ID: 24346355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative determination of lysophosphatidic acid by LC/ESI/MS/MS employing a reversed phase HPLC column.
    Shan L; Jaffe K; Li S; Davis L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Mar; 864(1-2):22-8. PubMed ID: 18262478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysophosphatidic acid plasma concentrations in healthy subjects: circadian rhythm and associations with demographic, anthropometric and biochemical parameters.
    Michalczyk A; Budkowska M; Dołęgowska B; Chlubek D; Safranow K
    Lipids Health Dis; 2017 Jul; 16(1):140. PubMed ID: 28732508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast-enhanced ultrasonography in differential diagnosis of benign and malignant ovarian tumors.
    Qiao JJ; Yu J; Yu Z; Li N; Song C; Li M
    PLoS One; 2015; 10(3):e0118872. PubMed ID: 25764442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.